Browse the evidence

Inhibition of ceramide biosynthesis improves glucose tolerance and insulin sensitivity in obese mice by restoring insulin signaling (Akt phosphorylation) in the liver and muscle.

Blocking ceramide production improves how the body handles sugar and insulin in obese mice, primarily by fixing signaling in the liver and muscles.

Elevated ceramide levels contribute to the expression of inflammatory adipokines MCP-1 and PAI-1, while TNF-alpha acts upstream of ceramide biosynthesis.

High ceramide levels drive inflammation markers like MCP-1 and PAI-1 in fat tissue, while TNF-alpha triggers ceramide production.

Inhibition of ceramide biosynthesis improves hepatic steatosis (fatty liver) in obese mice, associated with reduced hepatic SOCS-3 expression.

Blocking ceramide production reduces fatty liver in obese mice, likely by lowering SOCS-3 levels.

Global efforts to reduce malnutrition have been more than offset by a rapidly rising obesity burden, resulting in a widening 'double burden' of disease where obesity-related disability-adjusted life years (DALYs) now vastly exceed malnutrition-related DALYs.

Global health strategies must stop treating hunger and obesity as separate issues. As countries develop and reduce starvation, they often swing into obesity epidemics. Effective policy requires a unified approach that ensures food security while simultaneously preventing the shift toward unhealthy, obesity-driving diets, particularly in low-to-middle income regions undergoing rapid economic change.

Obesity-related mortality and DALYs are highest in low-to-middle Socio-Demographic Index (SDI) countries, whereas malnutrition burden is concentrated in low SDI countries, creating a distinct geographic and socioeconomic split in the double burden of disease.

Public health in developing nations must anticipate the 'nutrition transition.' As economies grow, access to food increases, but often shifts toward unhealthy, obesity-driving diets. Policies must simultaneously address undernutrition and prevent the rise of obesity, as the burden of obesity-related death peaks in middle-income countries, not the wealthiest ones.

There is no significant association between sugar-sweetened beverage consumption and the risk of total stroke.

While reducing SSBs is crucial for heart health, current evidence does not show a significant link to stroke risk in the general population. However, since SSBs increase blood pressure and heart disease risk, avoiding them remains the best strategy for overall cardiovascular health.

Small nucleolar size is a conserved cellular hallmark of longevity and metabolic health across multiple species, including C. elegans, Drosophila, mice, and humans.

This research identifies small nucleoli as a marker of longevity and metabolic health. While you cannot directly 'exercise' your nucleoli, interventions that promote longevity—such as dietary restriction and exercise—are associated with this cellular feature. For humans, combining modest caloric restriction with increased physical activity was linked to smaller nucleoli in muscle biopsies, suggesting this cellular change is a reversible marker of metabolic improvement.

GLP-1 analogs exert pleiotropic effects on multiple tissues beyond glucose regulation, including neuroprotection, cardiac improvement, and metabolic reprogramming, mediated by cAMP/PKA/EPAC signaling pathways.

GLP-1 analogs (like semaglutide or liraglutide) are not just for blood sugar. They work by mimicking a natural hormone to signal your brain, heart, and gut. This leads to reduced appetite, better heart function, and potential protection for your brain and kidneys. Consistency is key because these benefits build over time through sustained receptor activation.

GLP-1 analogs protect pancreatic beta-cells from apoptosis and ER stress by promoting autophagy and metabolic reprogramming, thereby preserving beta-cell mass in Type 2 Diabetes.

GLP-1 analogs help keep your remaining insulin-producing cells alive by reducing stress and clearing out damaged cellular components (autophagy). This helps maintain your body's natural ability to produce insulin over time, which is crucial for long-term diabetes management.

Leptin is required to metabolically license activated effector T cells for glucose uptake and cytokine production, linking systemic nutritional status to immune function.

For optimal immune function, especially during stress or dieting, maintaining healthy leptin levels through adequate energy intake is crucial. Simply eating enough food might not be enough if hormonal signaling is disrupted; leptin acts as a necessary 'key' to allow immune cells to use energy effectively.

Dose-dependent supplementation with prebiotic fibers (inulin and oligofructose) increases satiety hormones (GLP-1, PYY) and alters gut microbiota (increasing Bacteroidetes, decreasing Firmicutes) in lean and obese states, but does not significantly reduce body fat or body weight in a monogenic obesity model.

Eating prebiotic fibers (like inulin) can improve your gut health and boost satiety hormones, which is beneficial for metabolic regulation. However, in some cases, especially with certain genetic predispositions to obesity, this may not automatically result in weight loss. Focus on the health benefits of fiber rather than expecting it to be a standalone weight-loss solution.

Prebiotic fiber supplementation reduces energy intake by lowering the energy density of the diet, rather than by reducing food volume intake, as food intake (grams) often increases or stays the same.

Adding prebiotic fibers to your diet can help you consume fewer calories without necessarily feeling like you are eating less food. This is because fiber has fewer calories per gram than other carbohydrates. It is a strategy of energy dilution, not just volume restriction.

Individualized behavioral interventions (such as social marketing or diet plans) are ineffective at reversing population-level obesity trends because they ignore the structural, commercial, and environmental drivers of energy imbalance.

Do not rely solely on willpower or diet plans to solve the obesity epidemic. Recognize that individual effort is insufficient against a commercial environment designed to promote overconsumption. Advocate for structural changes like food labeling, marketing restrictions, and urban planning that supports physical activity.

High-protein diets do not provide superior weight loss compared to other diets; any initial weight loss is primarily due to fluid loss, caloric restriction, and ketosis-induced appetite suppression rather than the protein content itself.

You do not need to follow a high-protein diet to lose weight. While high-protein diets can help you lose weight, they do so by helping you eat fewer calories, not because protein itself burns fat. Focus on a sustainable caloric deficit. If a high-protein diet helps you eat less, it can be a tool, but it is not superior to other diets that also create a caloric deficit.

High-protein diets, particularly those relying on animal sources, increase the risk of adverse health outcomes including elevated LDL cholesterol, gout, osteoporosis, and renal stress.

If you choose a high-protein diet, be aware of the potential side effects. Eating too much animal protein can raise bad cholesterol, increase gout risk, and stress the kidneys. People with existing kidney or heart conditions should avoid these diets. Ensure you are getting enough fiber and nutrients from other food groups.

High intake of red meat (both processed and unprocessed) is associated with increased all-cause mortality and mortality from nine specific causes, including cancer, cardiovascular disease, and respiratory disease.

If you eat red meat, consider reducing your intake. The study suggests that replacing red meat with white meat (especially unprocessed poultry or fish) lowers the risk of death from various causes, including heart disease and cancer, without needing to cut total meat consumption.

Heme iron and nitrate/nitrite from processed meat independently contribute to increased mortality risk, with nitrate accounting for a larger proportion of the risk from processed red meat.

The health risks of processed red meat are largely due to heme iron and added nitrates/nitrites. Choosing unprocessed meats or those without added nitrates may mitigate these specific risks.

Chronic elevation of reactive oxygen species (ROS) in adipose tissue causes insulin resistance and metabolic dysfunction by impairing insulin signaling and reducing adiponectin secretion.

In obesity, fat cells produce too much oxidative stress (ROS) over time, which blocks insulin from working properly. This isn't about 'bad' stress in small amounts, but chronic overload. Managing weight and reducing fat mass is the primary way to reduce this specific source of oxidative stress and restore insulin sensitivity.

Hypertrophied (enlarged) adipocytes are a significant source of ROS production, primarily via NADPH oxidase (Nox4) and mitochondrial dysfunction, driving local inflammation and metabolic dysfunction.

Large fat cells produce more oxidative stress than small ones. This internal stress contributes to the inflammation and metabolic problems associated with obesity. Reducing fat cell size through weight loss can mitigate this specific source of oxidative stress.

Physiological levels of ROS act as beneficial second messengers that promote insulin sensitivity and adipogenesis, whereas chronic elevation leads to insulin resistance.

Not all oxidative stress is bad. Small amounts of ROS are necessary for normal cellular functions like insulin signaling and fat cell formation. The problem in obesity is the chronic, excessive production that overwhelms these beneficial signals.

Approximately 30% of illicit anabolic-androgenic steroid (AAS) users develop a distinct dependence syndrome characterized by chronic use despite adverse physical and psychosocial effects.

If you are using AAS illicitly, recognize that about 30% of users develop a dependence syndrome. This involves continuing use despite negative health or social consequences, experiencing withdrawal symptoms (fatigue, depression, loss of libido) when stopping, and spending significant time obtaining or using the drug. Standard addiction criteria need adaptation because AAS do not cause acute intoxication. If you are struggling with use, seek help from professionals familiar with AAS culture to address both the physical dependence and the underlying body image concerns.

AAS dependence shares significant neurobiological mechanisms with opioid dependence, including opioid-like withdrawal symptoms and cross-sensitization.

The brain mechanisms underlying AAS dependence overlap with those of opioid addiction. This may explain why AAS users have high rates of opioid abuse and why AAS withdrawal can resemble opioid withdrawal. Treatment strategies for opioid dependence may have relevance for AAS dependence.

AAS dependence is associated with higher rates of conduct disorder, antisocial traits, and other substance dependencies, particularly opioid dependence.

AAS dependence often co-occurs with other mental health and substance use issues, such as opioid dependence and conduct disorder. Addressing these comorbidities is crucial for effective treatment of AAS dependence.

In patients with cirrhosis, sarcopenia is driven by a multifactorial imbalance between protein synthesis and breakdown, specifically involving hyperammonemia, increased autophagy, and impaired mitochondrial function, rather than just caloric deficit.

For cirrhosis patients, muscle loss is a complex biological failure, not just a diet problem. Treatment requires addressing the root causes like ammonia levels and inflammation, not just increasing calories.